Inhalational anthrax: Epidemiology, diagnosis, and management

Chest

Volumn 116, Issue 5, 1999, Pages 1369-1376

  Shafazand, Shirin ^a   Doyle, Ramona ^a   Ruoss, Stephen ^a   Weinacker, Ann ^a   Raffin, Thomas A ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anthrax; Bacillus species; Inhalational anthrax; Mediastinal hemorrhage; Mediastinal widening

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; PENICILLIN G; STREPTOMYCIN; SULFAMETHOXAZOLE; TRIMETHOPRIM; VACCINE;

ANTHRAX; ANTIBIOTIC THERAPY; BACILLUS ANTHRACIS; BACTERIAL SPORE; BIOLOGICAL WARFARE; BLEEDING; DEATH; DISEASE COURSE; DYSPNEA; EDEMA; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HYPOTENSION; INHALATION; LUNG DISEASE; LYMPHADENITIS; MEDIASTINITIS; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; SEPTIC SHOCK; SKIN DISEASE; SYMPTOMATOLOGY; THORAX RADIOGRAPHY; TREATMENT PLANNING; VACCINATION;

EID: 0032718090     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.116.5.1369     Document Type: Article

References (36)

1. 1 Christopher GW, Cieslack TJ, Pavlin JA, et al. Biological warfare: a historical perspective. JAMA 1997; 278:412-417
2. 2 Clement D. Bioterrorism: the danger hits home. Minn Med 1998; 81:12-17
3. 3 Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278:399-411
4. 4 Health aspects of chemical and biological weapons: report of WHO Group of Consultants. Geneva, Switzerland: World Health Organization, 1970; 72, 99
5. 5 Kaufmann AF, Meltzer MI, Schmid GP. The economic impact of a bioterrorist attack: are prevention and past attack programs justifiable? Emerg Infect Dis 1997; 3:83-94
6. 6 Direhx JH. Virgil on Anthrax. Am J Dermatopathol 1981; 3:191-195
7. 7 Zydowicz D. Anthrax: a disease from antiquity visits the modern world. Minn Med 1998; 81:19-20
8. 8 Eurich FW. The history of anthrax in the wool industry of Bradford, and of its control. Lancet: January 2, 1926; 57-58
9. 9 Titball RW, Manchel RJ. Factors Affecting the Germination of Spores of Bacillus anthracis. J Appl Bacteriol 1987; 62:269-273
10. 10 LaForce FM. Anthrax. Clin Infect Dis 1994; 19:1009-1014
11. 11 Penn CC, Klotz SA. Anthrax pneumonia. Semin Respir Infect 1997; 12:28-30
12. 12 Pile JC, Malone JD, Eitzen EM, et al. Anthrax as a potential biological warfare agent. Arch Intern Med 1998; 158:429-434
13. 13 Gold H. Anthrax: a report of one hundred seventeen cases. Arch Intern Med 1955; 96:387-396
14. 14 Baron EJ, Finegold SM. Diagnostic microbiology. 8th ed. St. Louis, MO: Mosby Year-Book, 1986; 451-454
15. 15 Koneman EW. Color atlas, and textbook of diagnostic microbiology. 2nd ed. Philadelphia, PA: JB Lippincott, 1983; 338-340
16. 16 Myrvik QN, Weiser RS. Fundamentals of medical bacteriology and mycology. 2nd ed. Philadelphia, PA: Lea and Febiger, 1988; 251-257
17. 17 Stanley JL, Smith H. Purification of factor 1 and recognition of a third factor of the anthrax toxin. J Gen Microbiol 1961; 26:49-66
18. 18 Hanna P. Anthrax pathogenesis, and host response. Curr Top Microbiol Immunol 1998; 225:13-35
19. 19 Leppla SH. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations in eukaryotic cells. Proc Natl Acad Sci USA 1982; 79:3102-3166
20. 20 Hanna PC, Acosta D, Collier RJ. On the role of macrophages in anthrax. Proc Natl Acad Sci USA 1993; 90:10198-10201
21. 21 Duesbery NS, Webb CP, Leppla SH, et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998; 280:734-737
22. 22 Ross JM. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bacteriol 1957; 73:485-494
23. 23 Albrink WS, Goodlow RJ. Experimental inhalation anthrax in the chimpanzees. Am J Pathol 1959; 35:1055-1065
24. 24 Brachman PS. Inhalation. Ann NY Acad Sci 1980; 353:83-93
25. 25 Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266:1202-1208
26. 26 Fritz DL, Jaax NK, Lawrence WB, et al. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest 1995; 73:691-702
27. 27 Abramova FA, Grinberg LM, Yampolskaya OV, et al. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci USA 1993; 90:2291-2294
28. 28 Anthrax vaccine. Med Lett Drugs Ther 1998; 40:52-53
29. 29 Turnbull PCB. Anthrax vaccines: past, present and future. Vaccine 1991; 9:533-539
30. 30 Demicheli V, Rivetti D, Deeks JJ, et al. The effectiveness and safety of vaccines against human anthrax: a systemic review. Vaccine 1998; 16:880-884
31. 31 Shlyakhov EN, Rubenstein E. Human live anthrax vaccine in the former USSR. Vaccine 1994; 12:727-730.
32. 32 Brachman PS, Gold H, Plotkin SA, et al. Field evaluation of a human anthrax vaccine. Am J Public Health 1962; 52:632-645
33. 33 Ivins BE, Welkos SL, Little IF, et al. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect Immunol 1992; 60:662-668
34. 34 Friedlander AM, Welkos SL, Pitt ML, et al. Postexposure prophylaxis against experimental inhalational anthrax. J Infect Dis 1993; 167:1239-1242
35. 35 Centers for Disease Control, and Prevention. Bioterrorism alleging use of anthrax and interim guidelines for management: United States, 1998. Morb Mortal Wkly Rep 1999; 48:69-74
36. 36 Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 1999; 281: 1735-1745